The demonstrated single-agent activity of BIRD-2 in ABT-263-resistant SCLC cells further supports the value of developing novel therapeutic agents that function similar to BIRD-2 by disrupting the Bcl-2–IP3R interaction. This evidence concerns the gene BCL2 and small cell lung carcinoma.